Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Oct 23, 2021 5:35pm
152 Views
Post# 34041233

RE:RE:RE:Joseph Arena buys a Few

RE:RE:RE:Joseph Arena buys a Few

I am disappointed that the 3 new Board members bought because they have 12 months to get to the required ownership levels for being on our Board, and did nothing much beyond that.   But it's tiny and This is likely the last buying period prior to 1a results,  I would have liked to see a lot more buying and by a broader mgmt group, CEO, CFO, CMO, Chairwomen, Molson, all of them.  They should be ploughing back at least all the fees we are paying them and more.  Eat home cooking.  If you believe there is validity to the pipeline, insiders should show that signal to the market which doesn't believe anything they say.  

Count me very disappointed.   


SPCEO1 wrote: Trust me, they know more than we do. When they look around the board room, they see the same smiling (or frowning) faces that some saw on the cancer KOL call! 

These are pathetic buys. The only high conviction buy recently was from Paul during the offering when he picked up 40,000 shares. 

But unlike you, I will take pathetic insider buying over no insider buying.
 

palinc2000 wrote:

I would rather see NO insider buying than the laughable small purchases in the last 2 weeks.....Moreover since insiders are not allowed to purchase based on undisclosed material info then we can assume that what we know about Phase 1 is all there is at the moment

 





<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse